The design of clinical trials for cell transplantation into the central nervous system Authors
Cite this article as: Cesaro, P. Neurotherapeutics (2004) 1: 492. doi:10.1602/neurorx.1.4.492 Conclusions
Although initial excitement was raised in the medical and scientific communities by pilot trials using adrenal autografts (1980s) and fetal allograft (1990s), two controlled trials in PD patients demonstrated negative results, with the conclusion that today, cell therapy cannot be recommended for PD. Nevertheless, trials are still in progress for diseases like HD, stroke, MS, cord transection, epilepsy, and others. Human knowledge about the biology of stem cells and precursor cells is growing and we have more and more evidence that cell therapy could be useful in “repairing” brain lesions, not only by survival and integration of grafted neurons, but also by stimulation of resident precursors already present within the CNS.
The knowledge gathered from animal experiments is increasing, and several new directions may be taken. They can lead us to implant pure cell lines, with a reproducible amount, to get predicable clinical results, or to implant cells which are able to stimulate the intrinsic regenerative properties of the brain. The latter may not apply to diseases which directly affect all resident cells in the CNS (e.g., HD) but may be of critical importance for traumatic or vascular brain lesions. Finally, some of the trophic factors which may improve the survival of grafted cells could represent,
per se, a therapeutic alternative (e.g., GDNF, reelin). In a sense, their use means “to teach the brain to graft himself with its own cells.”
From a medical point of view, we have to transfer preclinical knowledge, ensuring a maximal security for the patients. This, as an ethical research, has to implement logical, comprehensive, highly controlled methods that need a complex organization. The transplantation teams should work as quickly as possible in the design of the trials, but must comply with, and not precede, the preclinical research.
Download to read the full article text References
Polgar S, Morris ME, Reilly S, Bilney B, Sanberg PR. Reconstructive neurosurgery for Parkinson’s disease: a systematic review and preliminary meta-analysis.
Brain Res Bull
60: 1–24, 2003.
Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, Fischman AJ, Thomas C, Feldman RG, Kassissieh S, Raineri R, Manhart C, Penney D, Fink JS, Isacson O. Transplantation of embryonic porcine mesencephalic tissue in patients with PD.
54: 1042–1050, 2000.
Bjorklund A, Lindvall O. Cell replacement therapies for central nervous system disorders.
3: 537–544, 2000.
Dunnet S. Transplantation of embryonic dopamine neurons: what we know from rats.
238: 65–74, 1991.
Folkerth RD, Durso R. Survival and proliferation of non-neural tissue with obstruction of cerebral ventricles in a parkinsonian patient treated with fetal allograft.
46: 1219–1224, 1996.
Shulkin DJ, Kinosian B, Glick H, Sirio C, Glen-Puschett C, Daly J. Explaining cost variations in clinical trials using severity of illness measures.
Clin Perform Qual Health Care
1: 134–137, 1993.
Brooks DJ, Salmon EP, Mathias CJ et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson’s disease, studied with PET.
113: 1539–1552, 1990.
Remy P, Samson Y, Hantraye P, Fontaine A, Defer G, Mangin J et al. Neural grafting in five parkinsonian patients: correlations between PET and clinical evolution.
38: 580–588, 1995.
Wenning G, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, Rothwell J, Brown R, Gustavvii B, Hagell P, Jahanshahi M, Sawle G, Björklund A, Brooks D, Marsden C, Quinn N, Lindvall O. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson’s disease.
42: 95–107, 1997.
Kordower J, Goetz C, Freeman T, Olanow C. Dopaminergic transplants in patients with Parkinson’s disease: neuroanatomical correlates of clinical recovery.
144: 41–46, 1997.
Kordower J, Rosenstein J, Collier T, Burke M, Chen E, Li J, Martel L, Levey A, Mufson E, Freeman T, Olanow C. Functional fetal nigral grafts in a patient with Parkinson’s disease: chemoanatomic, ultrastructural, and metabolic studies.
J Comp Neurol
37: 203–230, 1996.
Langston J, Widner H, Goetz C, Brooks D, Fahn S, Freeman T, Watts R. Core assessment program for intracerebral transplantations (CAPIT).
7: 2–13, 1992.
Defer G, Widner H, Marie R, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD).
14: 572–584, 1999.
Lindvall O. Cerebral implantation in movement disorders: state of the art.
14: 201–205, 1999.
Lindvall O, Sawle G, Widner H, Rothwell J, Björklund A, Brooks D, Brundin P, Frackowiak R, Marsden C, Odin P, Rehncrona S. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson’s disease.
35: 172–180, 1994.
Peschanski M, Defer G, N’Guyen J, Ricolfi F, Monfort J, Remy P et al. Bilateral motor improvement and alteration of
-dopa effect in two patients with Parkinson’s disease following intrastriatal transplantation of foetal ventral mesencephalon.
117: 487–499, 1994.
Defer G, Geny C, Ricolfi F, Fenelon G, Monfort J, Remy P, Villafane G, Jeny R, Samson Y, Gaston A, Degos J, Peschanski M, Cesaro P, Nguyen J. Long-term outcome of unilaterally transplanted parkinsonian patients.
119: 41–50, 1996.
Freed C, Breeze R, Rosenberg N, Schneck S, Kriek E, Qi J, Lone T, Zhang Y, Snyder J, Wells T, Ramig L, Thompson L, Maziotta J, Huang S, Grafton S, Brooks D, Sawle G, Schrotter G, Ansari A. Survival of implanted fetal dopamine cells and neurologic improvement 12–46 months after transplantation for Parkinson’s disease.
N Engl J Med
327: 1549–1555, 1992.
Freeman T, Olanow C, Hauser R, Nauert M, Smith D, Borlongan C, Sanberg P, Holt D, Kordower J, Vingerhoets F, Snow B, Calne D, Gauger L. Bilateral fetal nigral transplantation into the post-commissural putamen in Parkinson’s disease.
38: 379–388, 1995.
Piccini P, Brooks DJ, Bjorklund A et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient.
12: 1137–1140, 1999.
Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, Kupsch A, Crabb L, Odin P, Gustavii B, Björklund A, Brooks D, Marsden C, Oertel W, Quinn N, Rehncrona S, Lindvall O. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson’s disease.
123: 1380–1390, 2000.
Cochen V, Ribeiro MJ, Nguyen JP, Gurruchaga JM, Villafane G, Loc’h C, Defer G, Samson Y, Peschanski M, Hantraye P, Cesaro P, Remy P. Transplantation in Parkinson’s disease: PET changes correlate with the amount of grafted tissue.
18: 928–932, 2003.
Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, Widner H, Brundin P, Rothwell J, Odin P, Wenning G, Morrish P, Gustavii B, Björklund A, Brooks D, Marsden C, Quinn N, Lindvall O. Sequential bilateral transplantation in Parkinson’s disease: effects of the second graft.
122: 121–1132, 1999.
Freed C, Greene P, Breeze R, Tsai W, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski J, Eidelberg D, Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease.
N Engl J Med
344: 710–719, 2001.
Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease.
54: 403–414, 2003.
Kendall AL, Rayment FD, Torres EM, Baker HF, Ridley RM, Dunnett SB. Functional integration of striatal allografts in a primate model of Huntington’s disease.
4: 727–729, 1998.
Palfi S, Cond, F, Riche D, Brouillet E, Dautry C, Mittoux V et al. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington’s disease.
4: 963–966, 1998.
Onteniente B, Rasika S, Benchoua A, Guegan C. Molecular pathways in cerebral ischemia: cues to novel therapeutic strategies.
27: 33–72, 2003.
Savitz SI, Rosenbaum DM, Dinsmore JH, Wechsler LR, Caplan LR. Cell transplantation for stroke.
52: 266–275, 2002.
Lindvall O, Hagell P. cell replacement therapy in human neuro-degenerative disorders.
Clin Neurosci Res
2: 86–92, 2002.
Halfpenny C, Benn T, Scolding N. Cell transplantation, myelin repair, and multiple sclerosis.
1: 31–40, 2002.
Tai Y-T, Svendsen CN. Stem cells as apotential treatment of neurological disorders.
Curr Opin Pharmacol
4: 98–104, 2004.
Bachoud-Lévi A-C, Remy P, Nguyen J-P, Brugières P, Lefaucheur J-P, Bourdet C et al. Motor and cognitive improvements in patients with Huntington’ s disease after neural transplantation.
356: 1975–1979, 2000.
Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S et al. Bilateral human fetal striatal transplantation in Huntington’s disease.
58: 687–695, 2002.
Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured by PET in patients with Huntington’s disease.
113: 1405–1423, 1990.
Palfi S, Nguyen JP, Brugieres P, Le Guerinel C, Hantraye P, Remy P, Rostaing S, Defer GL, Cesaro P, Keravel Y, Peschanski M. MRI-stereotactical approach for neural grafting in basal ganglia disorders.
150: 272–281, 1998.
Bachoud-Lévi A-C, Déglon N, Nguyen J-P, Bloch J, Bourdet C, Winkel L, Remy P, Goddard M, Lefaucheur J-P, Brugières P, Baudic S, Cesaro P, Peschanski M, Aebischer P. Neuroprotective gene therapy for Huntington’s disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF.
Hum Gene Ther
11: 1723–1729, 2000.
Hong M, Mendez I. Double grafting of human fetal dopamine cells restores function and anatomy of the nigrostriatal pathway in the rodent model of Parkinson’s disease. Paper presented at the Sixth Annual Conference of the American Society for Neural Transplantation and Repair, Clearwater, FL, April, 1999.
Gaura V, Bachoud-Lévi A-C, Ribeiro M-J, Nguyen J-P, Frouin V, Baudic S, Brugières P, Mangin J-F, Boiss, M-F, Palfi S, Cesaro P, Samson, Y, Hantraye P, Peschanski M, Remy P. Striatal neural grafting improves cortical metabolism in Huntington’s disease patients.
127: 65–72, 2004.
Quinn N, Brown R, Craufurd D, Goldman S, Hodges J, Kieburtz K et al. Core assessment program for intracerebral transplantation in Huntington’s disease (CAPIT-HD).
11: 143–150, 1996.
Albin RL. Sham surgery controls: intracerebral grafting of fetal tissue for Parkinson’s disease and proposed criteria for use of sham surgery controls.
J Med Ethics
28: 322–325, 2002.
Azzouz M, Martin-Rendon E, Barber RD, Mitrophanous KA, Carter EE, Rohll JB, Kingsman SM, Kingsman AJ, Mazarakis ND. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic
-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson’s disease.
22: 10302–10312, 2002.
Gill SS, Patel NK, Hotton GR et al. Direct brain infusion of glial cell-line derived neurotrophic factor in Parkinson’s disease.
9: 589–595, 2003.
Sugaya K. Neuroreplacement therapy and stem cell biology under disease conditions.
Cell Mol Life Sci
60: 1891–1902, 2003.
PubMed CrossRef Copyright information
© The American Society for Experimental NeuroTherapeutics, Inc 2004